Megace
information and resources from the National Cancer Institute
megestrol acetate Bristol-Myers Squibb Aug 18 1971
|
|
|
|
news articles
Par Pharmaceutical Reports Sales and Earnings for 2005 Feb 28, 2006
PR Newswire (press release), ..."Based upon current planning assumptions, Par expects its initial branded pharmaceutical product, Megace ES, to achieve sales of approximately $70 million in ...
Is there any role for thalidomide as a monotherapy in the ... Mar 8, 2006
News-Medical.net, In this report by Lee and colleagues, thalidomide as a monotherapy is compared to medroxyprogesterone acetate (Megace). Of note, Megace ...
Par Pharmaceutical Reports Sales and Earnings for 2005 Feb 28, 2006
PR Newswire (press release), Fourth-Quarter, After-Tax, Non-Cash Charges of $25.0 Million for FineTech Divestiture and $5.8 Million for Asset Impairment Par Looks Forward to Megace(R) ES ...
UPDATE 1-TABLE-Par Pharmaceutical reports Q4 loss Feb 28, 2006
Reuters The company said it expects its initial branded pharmaceutical product, Megace ES, an appetite stimulant, to achieve sales of about $70 million in 2006. ...
Par Pharmaceutical Names Gerard A. Martino Chief Financial Officer Mar 16, 2006
PR Newswire (press release), In 2005, Par received approval for and introduced Megace(R) ES, its first branded pharmaceutical product, and expects to launch its second in 2006. ...
Study Suggests MPA is Effective Treatment for Hot Flashes Mar 6, 2006
eMaxHealth.com, Some newer antidepressants such as venlafaxine (Effexor®) and some progestin-based drugs such as megestrol acetate (Megace®) or MPA (Depo-Provera™) are non ...
Updates, advisories and surprises Feb 28, 2006
Investor's Business Daily (subscription) Par expects its initial branded pharmaceutical, the appetite stimulant Megace ES, to achieve sales of about $70 million in 2006. ...
Study Suggests MPA is Effective Treatment for Hot Flashes Feb 28, 2006
AScribe Some newer antidepressants such as venlafaxine (Effexor (r)) and some progestin-based drugs such as megestrol acetate (Megace(r)) or MPA (Depo-Provera(tm)) are ...
Q4 2005 Par Pharmaceutical Companies, Inc. Earnings Conference ... Feb 28, 2006
Business Wire (press release), The EPS forecast for 2006 is based on Megace ES sales reaching $70m. PRX believes that 2007 could be much larger than anticipated.
Patients With HIV-Associated Wasting Gain More Weight With ... Dec 19, 2005
Yahoo! News (press release) 575 mg/5mL (MA-CS 575 mg/5 mL) than those patients receiving megestrol acetate oral suspension 800 mg/20 mL (MA-OS 800 mg/5ml, Megace® oral suspension ...
New Antibiotic Candidate Shows Promise in Treating Clostridium ... Dec 19, 2005
PR Newswire (press release), ...specialty markets. In 2005, Par received approval for and introduced Megace(R) ES, its first branded pharmaceutical product. Through ...
Par to Distribute Generic Versions of Augmentin(R) and Amoxil(R) Dec 16, 2005
PR Newswire (press release), The company is also developing an additional line of branded pharmaceutical products, the first of which is Megace(R) ES, for specialty markets. ...
National Roundup Nov 23, 2005
Windy city Media Group, ...weight loss. According to a press release from Par Pharmaceutical, www.megacees.com showcases the stimulant Megace ES. The site ...
|
|
